IL115885A0 - Pharmaceutical compositions comprising carbazoles and cyclodextrins - Google Patents

Pharmaceutical compositions comprising carbazoles and cyclodextrins

Info

Publication number
IL115885A0
IL115885A0 IL11588595A IL11588595A IL115885A0 IL 115885 A0 IL115885 A0 IL 115885A0 IL 11588595 A IL11588595 A IL 11588595A IL 11588595 A IL11588595 A IL 11588595A IL 115885 A0 IL115885 A0 IL 115885A0
Authority
IL
Israel
Prior art keywords
carbazoles
cyclodextrins
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
IL11588595A
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL115885A0 publication Critical patent/IL115885A0/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL11588595A 1994-11-07 1995-11-06 Pharmaceutical compositions comprising carbazoles and cyclodextrins IL115885A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203242 1994-11-07

Publications (1)

Publication Number Publication Date
IL115885A0 true IL115885A0 (en) 1996-01-31

Family

ID=8217355

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11588595A IL115885A0 (en) 1994-11-07 1995-11-06 Pharmaceutical compositions comprising carbazoles and cyclodextrins

Country Status (5)

Country Link
AU (1) AU3846395A (en)
IL (1) IL115885A0 (en)
TR (1) TR199501376A2 (en)
WO (1) WO1996014090A1 (en)
ZA (1) ZA959388B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330596A (en) 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CN100572363C (en) 2000-11-17 2009-12-23 武田药品工业株式会社 Imdazole derivatives, Its Preparation Method And Use
US6960586B2 (en) 2000-11-20 2005-11-01 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
CA2431171A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
GEP20156250B (en) 2009-06-26 2015-02-25 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
BR112012009262A2 (en) * 2009-10-23 2019-09-24 Health Research Inc A method for inhibiting the proliferation of air-positive cancer cells in an individual diagnosed with or suspected to have air-positive cancer and a method for identifying whether an individual is a candidate for treatment with a composition.
JP5998137B2 (en) 2010-08-04 2016-09-28 ペルフィキュア ファーマシューティカルズ，インコーポレイテッド Combination therapy to treat prostate cancer
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
ES2656218T3 (en) 2011-04-28 2018-02-26 Novartis Ag 17 alpha-hydroxylase / C17,20-lyase inhibitors
WO2014158875A1 (en) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310635D0 (en) * 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU3846395A (en) 1996-05-31
WO1996014090A1 (en) 1996-05-17
TR199501376A2 (en) 1996-06-21
ZA959388B (en) 1997-05-06

Similar Documents

Publication Publication Date Title
IL114622A0 (en) Heteroaryl-oxazolidinones and pharmaceutical compositions containing them
IL119078A (en) Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
IL122485A0 (en) Arylsulfonylaminobenzene derivatives and pharmaceutical compositions containg the same
IL116851A (en) 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
HUP9900424A2 (en) Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them
IL135990A0 (en) Pharmaceutical compositions containing cyclodextrins and taxoids
AU5856898A (en) Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them
IL115885A0 (en) Pharmaceutical compositions comprising carbazoles and cyclodextrins
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
EP0755250A4 (en) Benzamide-containing pharmaceutical compositions
HUP9602196A2 (en) Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
IL120722A0 (en) Carbohydrate derivatives and pharmaceutical compositions containing them
GB9501286D0 (en) Pharmaceutical compositions and preparations thereof
IL115982A (en) Cyclolignan derivatives and pharmaceutical compositions containing them
ZA982457B (en) Pharmaceutical compositions containing propanaminde derivatives and cyclodextrin
HUP9802291A3 (en) Penicillaminamide derivatives and pharmaceutical compositions containing them
HUP0000275A3 (en) Phenanethridinium derivatives and pharmaceutical compositions containing them
IL117618A0 (en) Diphenylmethyl-azetidinone derivatives and pharmaceutical compositions containing the same
GB2295825B (en) Pharmaceutical compositions
IL115882A0 (en) Oxazolyl-and thiazolylimidazo-benzo-and thienodiazepines their manufacture and pharmaceutical compositions containing them
HUP9901968A3 (en) 2-thioxotetrahydropyrimidin-4-one derivatives and pharmaceutical compositions containing them
GB9400047D0 (en) Pharmaceutical compositions
IL117155A0 (en) Quinolizinone derivatives and pharmaceutical compositions containing the same
ZA974422B (en) Substituted-amidinobenzene derivative and pharmaceutical compositions thereof.